Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Moleculin Biotech, Inc. (Nasdaq: MBRX) is set to present at the Corporate Connect Webinar Series, hosted by Webull Financial, on February 11, 2026, at 1:20 PM EST. Walter Klemp, the company's Founder, President, CEO, and Chairman, will lead the presentation. This virtual conference, occurring from February 10-11, is part of Webull’s ongoing effort to connect self-directed investors with market insights using advanced trading tools and real-time data.

Moleculin is a Phase 3 clinical-stage biotech firm focused on developing therapies for challenging tumors and viral infections. The company's flagship product, Annamycin (naxtarubicin), is a next-generation anthracycline designed to circumvent drug resistance and avoid the cardiotoxic effects typically associated with existing therapies. Annamycin is currently under evaluation in the MIRACLE trial (MB-108), a pivotal Phase 3 study that explores its effectiveness in combination with cytarabine for treating relapsed or refractory acute myeloid leukemia (AML). Following encouraging results from a Phase 1B/2 study, Moleculin is progressing towards potential FDA approval for this treatment.

Moreover, Moleculin is advancing WP1066, an immune/transcription modulator targeting multiple cancers, including brain and pancreatic tumors. The company also boasts a robust pipeline, including WP1122, aimed at combating pathogenic viruses and certain cancers.

Webull Financial is committed to empowering traders with sophisticated, low-cost trading options and serves millions of users globally. Register for Moleculin's presentation through the Webull platform to gain insights into their promising drug development and what’s next for the company. For further details on Moleculin, visit their official website at www.moleculin.com or reach out to their investor relations team.

Moleculin Biotech, Inc. (Nasdaq: MBRX) presents an intriguing investment opportunity, especially with its participation in the Corporate Connect Webinar Series hosted by Webull Financial on February 11, 2026. The event provides a platform for the company's leadership, including CEO Walter Klemp, to share valuable insights about ongoing developments in its clinical pipeline and future prospects.

Moleculin is advancing key therapeutic candidates, particularly its lead program, Annamycin, which is designed to treat hard-to-manage conditions like relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma. The ongoing Phase 3 MIRACLE Trial marks a pivotal moment in the company's journey, presenting a substantial opportunity for growth, especially if results indicate efficacy and safety in combination with cytarabine. Given the FDA's previous feedback during the Phase 1B/2 study, investors may anticipate a more defined trajectory toward potential approval, which can significantly enhance shareholder value.

Moreover, the company’s research extends to various cancer types and pathogenic viruses through candidates like WP1066 and WP1122. This diversified pipeline mitigates risks typically associated with biopharmaceutical investments and positions Moleculin for a broader market appeal—critical for attracting institutional investments.

Investors looking to capitalize on future growth should pay close attention to the upcoming webinar as it could provide insights into the company's operational execution and strategic goals. Additionally, following Moleculin's performance and market response to trial results will be crucial. It's advisable to assess entry points, especially leading up to key announcements or data releases that could drive volatility.

In conclusion, Moleculin Biotech, with its ambitious pipeline and committed leadership, presents a compelling opportunity in the biotech sector. Investors should remain vigilant and informed as developments unfold.